Shenzhen Lifotronic Technology Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Shenzhen Lifotronic Technology heeft een totaal eigen vermogen van CN¥1.9B en een totale schuld van CN¥627.0M, wat de schuld-eigenvermogensverhouding op 32.2% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥2.8B en CN¥873.8M. De EBIT Shenzhen Lifotronic Technology is CN¥372.7M waardoor de rentedekking -10 is. Het heeft contanten en kortetermijnbeleggingen van CN¥1.7B.

Belangrijke informatie

32.2%

Verhouding schuld/eigen vermogen

CN¥627.00m

Schuld

Rente dekkingsratio	-10x
Contant	CN¥1.73b
Aandelen	CN¥1.95b
Totaal verplichtingen	CN¥873.76m
Totaal activa	CN¥2.82b

Recente financiële gezondheidsupdates

Is Shenzhen Lifotronic Technology (SHSE:688389) A Risky Investment?

Oct 24

Recent updates

Is Shenzhen Lifotronic Technology (SHSE:688389) A Risky Investment?

Oct 24

Investors Still Aren't Entirely Convinced By Shenzhen Lifotronic Technology Co., Ltd.'s (SHSE:688389) Earnings Despite 33% Price Jump

Oct 02

Shenzhen Lifotronic Technology (SHSE:688389) Is Experiencing Growth In Returns On Capital

Aug 16

Is Shenzhen Lifotronic Technology Co., Ltd. (SHSE:688389) Trading At A 47% Discount?

Jul 25

Why Investors Shouldn't Be Surprised By Shenzhen Lifotronic Technology Co., Ltd.'s (SHSE:688389) Low P/E

May 24

Shenzhen Lifotronic Technology (SHSE:688389) Might Have The Makings Of A Multi-Bagger

Apr 17

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥2.1B ) 688389 } overtreffen de korte termijn passiva ( CN¥870.2M ).

Langlopende schulden: De kortetermijnactiva 688389 ( CN¥2.1B ) overtreffen de langetermijnschulden ( CN¥3.5M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 688389 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 688389 is de afgelopen 5 jaar gestegen van 0% naar 32.2%.

Schuldendekking: De schuld van 688389 wordt goed gedekt door de operationele kasstroom ( 56.9% ).

Rentedekking: 688389 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

Shenzhen Lifotronic Technology Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Shenzhen Lifotronic Technology (SHSE:688389) A Risky Investment?

Recent updates

Price target increased by 7.5% to CN¥22.45

Third quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.16 in 3Q 2023)

Is Shenzhen Lifotronic Technology (SHSE:688389) A Risky Investment?

Investor sentiment deteriorates as stock falls 20%

Investors Still Aren't Entirely Convinced By Shenzhen Lifotronic Technology Co., Ltd.'s (SHSE:688389) Earnings Despite 33% Price Jump

New minor risk - Share price stability

Shenzhen Lifotronic Technology Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 19%

Price target decreased by 12% to CN¥20.87

Second quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in 2Q 2023)

Shenzhen Lifotronic Technology (SHSE:688389) Is Experiencing Growth In Returns On Capital

Is Shenzhen Lifotronic Technology Co., Ltd. (SHSE:688389) Trading At A 47% Discount?

Shenzhen Lifotronic Technology Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Why Investors Shouldn't Be Surprised By Shenzhen Lifotronic Technology Co., Ltd.'s (SHSE:688389) Low P/E

Upcoming dividend of CN¥0.28 per share

First quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.21 in 1Q 2023)

Shenzhen Lifotronic Technology (SHSE:688389) Might Have The Makings Of A Multi-Bagger

Shenzhen Lifotronic Technology Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Shenzhen Lifotronic Technology Co., Ltd., Annual General Meeting, Apr 12, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 16%

Now 21% undervalued

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.12 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.079 in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.16 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.09 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.079 (vs CN¥0.07 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS misses analyst expectations

Full year 2021 earnings: EPS misses analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.06 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.071 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.09 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.34 (vs CN¥0.26 in FY 2019)

New 90-day high: CN¥24.00

Investor sentiment deteriorated over the past week

New 90-day low: CN¥18.77

New 90-day low: CN¥18.85

New 90-day low: CN¥24.90

Third quarter earnings released

Shenzhen Lifotronic Technology Co., Ltd. to Report Q3, 2020 Results on Oct 17, 2020

New 90-day low - CN¥27.07

First half earnings released

Shenzhen Lifotronic Technology Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven